Introduction
heterogeneous disease, TNBC, death, breast cancer
TRIPLE-NEGATIVE BREAST CANCER, RECURRENCE, METASTASES, BREAST CANCER
Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by lack of or minimal expression of estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2). It accounts for almost 15%−20% of all breast cancer subtypes and is more aggressive than other subtypes, with a higher risk of recurrence, early metastases, and developing drug resistanceImmune checkpoint inhibitors (ICIs) have been established as a part of the standard of care for treating breast cancer. In patients with early TNBC, the KEYNOTE-522 and IMpassion031 trials demonstrated a higher pCR with neoadjuvant pembrolizumab (an anti-progression cell death 1 [PD-1] inhibitor) or atezolizumab (an anti-programmed death ligand-1 [PD-L1] inhibitor) when combined with chemotherapyAnthracycline combined with taxanes is a common chemotherapy regimen for the treatment of TNBC. However, there is a lack of research on combining ICIs with anthracycline and taxanes in the neoadjuvant setting. Herein, we conducted this single-arm phase II study to evaluate the efficacy and safety of neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin chemotherapy in patients with early TNBC. We reported here the perioperative outcomes of neoadjuvant camrelizumab plus chemotherapy. The trial is still ongoing and being followed up.In this study, neoadjuvant therapy with camrelizumab plus nab-paclitaxel and epirubicin results in a pCR rate of 64.1%, with a manageable safety profile. This study supports the feasibility of study treatment in early TNBC.